Cited by 807Epigenetics and DNA MethylationCancer-related gene regulationChromatin Remodeling and Cancer

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

Knutson, Sarah K, Wigle, Tim J, Warholic, Natalie M, Sneeringer, Christopher J, Allain, Christina J, Klaus, Christine R, Sacks, Joelle D, Raimondi, Alejandra, Majer, Christina R, Song, Jeffrey, Scott, Margaret Porter, Jin, Lei, Smith, Jesse J, Olhava, Edward J, Chesworth, Richard, Moyer, Mikel P, Richon, Victoria M, Copeland, Robert A, Keilhack, Heike, Pollock, Roy M, Kuntz, Kevin W·2012·Nature Chemical Biology

DOI 10.1038/nchembio.1084

Open this paper in CoChat — free account

Abstract

EZH2 catalyzes trimethylation of histone H3 lysine 27 (H3K27). Point mutations of EZH2 at Tyr641 and Ala677 occur in subpopulations of non-Hodgkin's lymphoma, where they drive H3K27 hypertrimethylation. Here we report the discovery of EPZ005687, a potent inhibitor of EZH2 (K(i) of 24 nM). EPZ005687 has greater than 500-fold selectivity against 15 other protein methyltransferases and has 50-fold selectivity against the closely related enzyme EZH1. The compound reduces H3K27 methylation in various lymphoma cells; this translates into apoptotic cell killing in heterozygous Tyr641 or Ala677 mutant cells, with minimal effects on the proliferation of wild-type cells. These data suggest that genetic alteration of EZH2 (for example, mutations at Tyr641 or Ala677) results in a critical dependency on enzymatic activity for proliferation (that is, the equivalent of oncogene addiction), thus portending the clinical use of EZH2 inhibitors for cancers in which EZH2 is genetically altered.

Integrity signals

Registry

Crossref · 10.1038/nchembio.1084

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors
Ben‐Porath, I., Thomson, M., Carey, V. J., Ge, R., Bell, G. W., Regev, A., & Weinberg, R. A. (2008) · Nature Genetics · doi:10.1038/ng.127 · Cited by 2,571
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
Morin, R. D., Johnson, N. A., Severson, T., Mungall, A. J. J., An, J., Goya, R., Paul, J. E., Boyle, M., Woolcock, B. W., Kuchenbauer, F. C., et al. (2010) · Nature Genetics · doi:10.1038/ng.518 · Cited by 1,719
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells
Kleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., Ghosh, D., Sewalt, R. G. A. B., Otte, A. P., Hayes, D. F., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1933744100 · Cited by 1,649
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., Corbett, R. D., Johnson, N. A., Severson, T. M., Chiu, R., Field, M., et al. (2011) · Nature · doi:10.1038/nature10351 · Cited by 1,614
Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein
Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2002) · Genes & Development · doi:10.1101/gad.1035902 · Cited by 1,596
UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development
Agger, K., Cloos, P. A., Christensen, J. F., Pasini, D., Rose, S., Rappsilber, J., Issaeva, I., Canaani, E., Salcini, A. E., & Helin, K. (2007) · Nature · doi:10.1038/nature06145 · Cited by 1,392

Flagged first, then by citations

Show all 46 references

Sorted by citations

Items 201–300 of 807

Ezh2 Inhibition by Tazemetostat: Mechanisms of Action, Safety and Efficacy in Relapsed/refractory Follicular Lymphoma
Julia, E., & Salles, G. A. (2021) · Future Oncology · doi:10.2217/fon-2020-1244 · Cited by 87
The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression?
Xu, S., & Tang, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.745187 · Cited by 87
Targeting cholangiocarcinoma
Mertens, J. C., Ilyas, S. I., & Gores, G. J. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.08.027 · Cited by 80
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function
Isshiki, Y., Chen, X., Teater, M. R., Karagiannidis, I., Nam, H. S., Cai, W., Meydan, C., Xia, M., Shen, H., Gutierrez, J., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.11.006 · Cited by 88
Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors
Baker, T. E., Nerle, S., Pritchard, J. R., Zhao, B., Rivera, V. M., Garner, A. P., & Gonzalvez, F. (2015) · Oncotarget · doi:10.18632/oncotarget.5066 · Cited by 80
EZH2 regulates neuroblastoma cell differentiation via NTRK1 promoter epigenetic modifications
Li, Z., Takenobu, H., Setyawati, A. N., Akita, N., Haruta, M., Satoh, S., Shinno, Y., Chikaraishi, K., Mukae, K., Akter, J., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0133-3 · Cited by 79
Exploiting an Allosteric Binding Site of PRMT3 Yields Potent and Selective Inhibitors
Liu, F., Li, F., Ma, A., Dobrovetsky, E., Dong, A., Gao, C., Korboukh, I., Liu, J., Smil, D. V., Brown, P. J., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3018332 · Cited by 78
Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition
Amatangelo, M. D., Garipov, A., Li, H., Conejo-Garcia, J. R., Speicher, D. W., & Zhang, R. (2013) · Cell Cycle · doi:10.4161/cc.25163 · Cited by 80
Chromatin modifiers and the promise of epigenetic therapy in acute leukemia
Greenblatt, S. M., & Nimer, S. D. (2014) · Leukemia · doi:10.1038/leu.2014.94 · Cited by 83
Structure, mechanism, and regulation of polycomb-repressive complex 2
Moritz, L., & Trievel, R. C. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r117.800367 · Cited by 84
B cells in chronic graft-versus-host disease
McManigle, W. C., Youssef, A., & Sarantopoulos, S. (2019) · Human Immunology · doi:10.1016/j.humimm.2019.03.003 · Cited by 81
DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment
Sarno, F., Nebbioso, A., & Altucci, L. (2019) · Epigenetics · doi:10.1080/15592294.2019.1699991 · Cited by 76
Epigenetic regulation of endothelial‐cell‐mediated vascular repair
Fraineau, S., Palii, C. G., Allan, D., & Brand, M. (2014) · FEBS Journal · doi:10.1111/febs.13183 · Cited by 80
Targeting epigenetic regulations in cancer
Ning, B., Li, W., Zhao, W., & Wang, R. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv116 · Cited by 77
Epigenetic Therapy for Epithelioid Sarcoma
Rothbart, S. B., & Baylin, S. B. (2020) · Cell · doi:10.1016/j.cell.2020.03.042 · Cited by 76
HDAC Inhibition to Prime Immune Checkpoint Inhibitors
Borcoman, E., Kamal, M., Marret, G., Dupain, C., Castel-Ajgal, Z., & Le Tourneau, C. (2021) · Cancers · doi:10.3390/cancers14010066 · Cited by 75
Molecular pathogenesis of germinal center‐derived B cell lymphomas
Pasqualucci, L. (2019) · Immunological Reviews · doi:10.1111/imr.12745 · Cited by 81
ABCB 1 and ABCG 2 restrict the brain penetration of a panel of novel EZH 2‐Inhibitors
Zhang, P., de Gooijer, M. C., Buil, L. C. M., Beijnen, J. H., Li, G., & van Tellingen, O. (2015) · International Journal of Cancer · doi:10.1002/ijc.29566 · Cited by 75
Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma
Kawano, S., Grassian, A. R., Tsuda, M., Knutson, S. K., Warholic, N. M., Kuznetsov, G., Xu, S., Xiao, Y., Pollock, R. M., Smith, J. S., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158888 · Cited by 75
Self-citation
Metabolic Mechanisms of Epigenetic Regulation
Meier, J. L. (2013) · ACS Chemical Biology · doi:10.1021/cb400689r · Cited by 75
The Emerging Role of Epigenetics in the Regulation of Female Puberty
Lomniczi, A., & Ojeda, S. R. (2015) · Endocrine development · doi:10.1159/000438840 · Cited by 75
Epigenetic pathways and glioblastoma treatment
Clarke, J., Penas, C., Pastori, C., Komotar, R. J., Bregy, A., Shah, A. H., Wahlestedt, C., & Ayad, N. G. (2013) · Epigenetics · doi:10.4161/epi.25440 · Cited by 72
Targeting Histone Methylation in Cancer
McCabe, M. T., Mohammad, H. P., Barbash, O., & Kruger, R. G. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000283 · Cited by 76
Long Non-Coding RNAs: the New Horizon of Gene Regulation in Ovarian Cancer
Worku, T., Bhattarai, D., Ayers, D., Wang, K., Wang, C., Rehman, Z. U., Talpur, H. S., & Yang, L. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000485395 · Cited by 72
Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications
Garcia‐Vilas, J. A., & Medina, M. Á. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i33.3695 · Cited by 72
Symphony of epigenetic and metabolic regulation—interaction between the histone methyltransferase EZH2 and metabolism of tumor
Zhang, T., Gong, Y., Meng, H., Li, C., & Xue, L. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00862-0 · Cited by 75
EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL
Brach, D., Johnston-Blackwell, D., Drew, A., Lingaraj, T., Motwani, V., Warholic, N. M., Feldman, I., Plescia, C., Smith, J. J., Copeland, R. A., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0840 · Cited by 70
Self-citation
Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics
Copeland, R. A., Moyer, M. P., & Richon, V. M. (2012) · Oncogene · doi:10.1038/onc.2012.552 · Cited by 71
Self-citation
Structure of the PRC2 complex and application to drug discovery
Shi, Y., Wang, X., Zhuang, Y., Jiang, Y., Melcher, K., & Xu, H. E. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.7 · Cited by 75
Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas
Knutson, S. K., Warholic, N. M., Johnston, L. D., Klaus, C. R., Wigle, T. J., Iwanowicz, D., Littlefield, B. A., Porter-Scott, M., Smith, J. J., Moyer, M. P., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111840 · Cited by 71
Self-citation
Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS
Ciarapica, R., Carcarino, E., Adesso, L., Salvo, M. D., Bracaglia, G., Leoncini, P. P., Dall’Agnese, A., Verginelli, F., Milano, G. M., Boldrini, R., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-139 · Cited by 72
Epigenetic pathways in macrophages emerge as novel targets in atherosclerosis
Neele, A. E., den Bossche, J. V., Hoeksema, M. A., & de Winther, M. P. J. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.101 · Cited by 72
Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer
Liu, Q., Wang, G., Li, Q., Jiang, W., Kim, J., Wang, R., Zhu, S. L., Wang, X., Lin, Y., Yang, Y., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32118 · Cited by 69
The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx)
Ciarapica, R., Salvo, M. D., Carcarino, E., Bracaglia, G., Adesso, L., Leoncini, P. P., Dall’Agnese, A., Walters, Z. S., Verginelli, F., Sio, L. D., et al. (2013) · Oncogene · doi:10.1038/onc.2013.471 · Cited by 70
Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine
Coyle, K. M., Boudreau, J. E., & Marcato, P. (2017) · BioMed Research International · doi:10.1155/2017/9620870 · Cited by 72
Transcriptional Regulation at DSBs: Mechanisms and Consequences
Machour, F. E., & Ayoub, N. (2020) · Trends in Genetics · doi:10.1016/j.tig.2020.01.001 · Cited by 68
EZH2 in Bladder Cancer, a Promising Therapeutic Target
Martínez‐Fernández, M., Rubio, C., Segovia, C., López-Calderón, F., Dueñas, M., & Paramio, J. M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161126000 · Cited by 68
CRISPR/Cas9-Mediated Genome Editing of Epigenetic Factors for Cancer Therapy
Yao, S., He, Z., & Chen, C. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.067 · Cited by 70
Epigenetic Control of B Cell Development and B-Cell-Related Immune Disorders
Bao, Y., & Cao, X. (2015) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8494-7 · Cited by 68
Ezh2 Regulates Transcriptional and Posttranslational Expression of T-bet and Promotes Th1 Cell Responses Mediating Aplastic Anemia in Mice
Tong, Q., He, S., Xie, F., Mochizuki, K., Liu, Y., Mochizuki, I., Meng, L., Sun, H., Zhang, Y., Guo, Y., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302943 · Cited by 67
The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease
He, S., Xie, F., Liu, Y., Tong, Q., Mochizuki, K., Lapinski, P. E., Mani, R. S., Reddy, P. R., Mochizuki, I., Chinnaiyan, A. M., et al. (2013) · Blood · doi:10.1182/blood-2013-05-505180 · Cited by 67
The genetic basis of diffuse large B-cell lymphoma
Pasqualucci, L. (2013) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3283623d7f · Cited by 72
Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer
Oki, S., Sone, K., Oda, K., Hamamoto, R., Ikemura, M., Maeda, D., Takeuchi, M., Tanikawa, M., Mori‐Uchino, M., Nagasaka, K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16316 · Cited by 68
Exploiting epigenetic vulnerabilities for cancer therapeutics
Mair, B., Kubicek, S., & Nijman, S. M. B. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.01.001 · Cited by 66
Recent progress toward epigenetic therapies: the example of mixed lineage leukemia
Neff, T., & Armstrong, S. A. (2013) · Blood · doi:10.1182/blood-2013-02-474833 · Cited by 68
Targeting Triple-Negative Breast Cancer by a Novel Proteolysis Targeting Chimera Degrader of Enhancer of Zeste Homolog 2
Dale, B., Anderson, C., Park, K., Kanıskan, H. Ü., Ma, A., Shen, Y., Zhang, C., Xie, L., Chen, X., Yu, X., et al. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00100 · Cited by 66
Advances in biology, diagnosis and treatment of DLBCL
Shi, Y., Xu, Y. X., Shen, H., Jin, J., Tong, H., & Xie, W. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05880-z · Cited by 71
Discovery, design, and synthesis of indole-based EZH2 inhibitors
Gehling, V. S., Vaswani, R. G., Nasveschuk, C. G., Duplessis, M., Iyer, P., Balasubramanian, S., Zhao, F., Good, A. C., Campbell, R., Lee, C., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.06.056 · Cited by 67
Selective inhibition of EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast cancer
Song, X., Gao, T., Wang, N., Feng, Q., You, X., Ye, T., Lei, Q., Zhu, Y., Xiong, M., Xia, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep20864 · Cited by 65
Progress in epigenetic histone modification analysis by mass spectrometry for clinical investigations
Önder, Ö., Sidoli, S., Carroll, M. P., & Garcia, B. A. (2015) · Expert Review of Proteomics · doi:10.1586/14789450.2015.1084231 · Cited by 70
The Epigenetic Basis of Diffuse Large B-Cell Lymphoma
Jiang, Y., & Melnick, A. M. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.01.003 · Cited by 68
Structure–Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors
Yang, X., Li, F., Konze, K. D., Meslamani, J. E., Ma, A., Brown, P. J., Zhou, M., Arrowsmith, C. H., Kanıskan, H. Ü., Vedadi, M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00855 · Cited by 65
Di-methylation of CD147-K234 Promotes the Progression of NSCLC by Enhancing Lactate Export
Wang, K., Huang, W., Chen, R., Lin, P., Zhang, T., Ni, Y., Li, H., Wu, J., Sun, X., Geng, J., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.12.010 · Cited by 64
Targeting EZH2 for Cancer Therapy: Progress and Perspective
Li, C. H., & Chen, Y. (2015) · Current Protein and Peptide Science · doi:10.2174/1389203716666150409100233 · Cited by 63
The Multiple Facets of PRC2 Alterations in Cancers
Wassef, M. A., & Margueron, R. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.10.012 · Cited by 72
EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer
Wassef, M. A., Luscan, A., Aflaki, S., Zielinski, D., Jansen, P. W. T. C., Baymaz, H. I., Battistella, A., Kersouani, C., Servant, N., Wallace, M. R., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814634116 · Cited by 63
Discovery of precision targeting EZH2 degraders for triple-negative breast cancer
Wang, C., Chen, X., Liu, X., Lu, D., Li, S., Qu, L., Yin, F., Luo, H., Zhang, Y., Luo, Z., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114462 · Cited by 67
Discovery and Optimization of Tetramethylpiperidinyl Benzamides as Inhibitors of EZH2
Nasveschuk, C. G., Gagnon, A., Garapaty, S., Balasubramanian, S., Campbell, R., Lee, C., Zhao, F., Bergeron, L., Cummings, R. T., Trojer, P., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400494b · Cited by 63
Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia
Danis, E. P., Yamauchi, T., Echanique, K. A., Zhang, X., Haladyna, J. N., Riedel, S. S., Zhu, N., Xie, H., Orkin, S. H., Armstrong, S. A., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.064 · Cited by 64
Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies
Cani, A. K., Soliman, M., Hovelson, D. H., Liu, C., McDaniel, A. S., Haller, M. J., Bratley, J. V., Rahrig, S., Li, Q., Briceño, C. A., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.79 · Cited by 64
Polycomb complexes in normal and malignant hematopoiesis
Carlo, V. D., Mocavini, I., & Croce, L. D. (2018) · The Journal of Cell Biology · doi:10.1083/jcb.201808028 · Cited by 66
Chemical Probes of Histone Lysine Methyltransferases
Kanıskan, H. Ü., & Jin, J. J. (2014) · ACS Chemical Biology · doi:10.1021/cb500785t · Cited by 63
Small-Molecule Ligands of Methyl-Lysine Binding Proteins: Optimization of Selectivity for L3MBTL3
James, L. I., Korboukh, V. K., Krichevsky, L., Baughman, B. M., Herold, J. M., Norris, J. L., Jin, J. J., Kireev, D., Janzen, W. P., Arrowsmith, C. H., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400919p · Cited by 62
The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane
Fisher, M. L., Adhikary, G., Grun, D., Kaetzel, D. M., & Eckert, R. L. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22448 · Cited by 63
Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis
Lee, Y., Mok, M. T. S., Kang, W., Yang, W., Tang, W., Wu, F., Xu, L., Yan, M., Yu, Z., Lee, S.-D., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky589 · Cited by 58
Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer
Martin, M. C., Zeng, G., Yu, J., & Schiltz, G. E. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01344 · Cited by 64
Identification of a Population of Epidermal Squamous Cell Carcinoma Cells with Enhanced Potential for Tumor Formation
Adhikary, G., Grun, D., Kerr, C. L., Balasubramanian, S., Rorke, E. A., Vemuri, M. C., Boucher, S., Bickenbach, J. R., Hornyak, T. J., Xu, W., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084324 · Cited by 61
The controversial role of the Polycomb group proteins in transcription and cancer: how much do we not understand Polycomb proteins?
Scelfo, A., Piunti, A., & Pasini, D. (2014) · FEBS Journal · doi:10.1111/febs.13112 · Cited by 61
Structure-Guided Design of EED Binders Allosterically Inhibiting the Epigenetic Polycomb Repressive Complex 2 (PRC2) Methyltransferase
Lingel, A., Sendzik, M., Huang, Y. R., Shultz, M. D., Cantwell, J., Dillon, M. P., Fu, X., Fuller, J., Gabriel, T., Gu, J., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01473 · Cited by 61
Histone Lysine Methylation and Neurodevelopmental Disorders
Kim, J., Lee, J., Lee, I., Lee, S. B., & Cho, K. S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071404 · Cited by 65
Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation
Thomenius, M. J., Totman, J., Harvey, D. M., Mitchell, L. H., Riera, T. V., Cosmopoulos, K., Grassian, A. R., Klaus, C. R., Foley, M., Admirand, E. A., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197372 · Cited by 62
Self-citation
Survival of skin cancer stem cells requires the Ezh2 polycomb group protein
Adhikary, G., Grun, D., Balasubramanian, S., Kerr, C. L., Huang, J. M., & Eckert, R. L. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv064 · Cited by 60
Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2
Christofides, A., Karantanos, T., Bardhan, K., & Boussiotis, V. A. (2016) · Oncotarget · doi:10.18632/oncotarget.12928 · Cited by 61
ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer
Zhang, P., Xiao, Z., Wang, S., Zhang, M., Wei, Y., Hang, Q., Kim, J., Yao, F., Rodriguez‐Aguayo, C., Ton, B. N., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.078 · Cited by 62
Targeting epigenetic modulators using PROTAC degraders: Current status and future perspective
Webb, T., Craigon, C., & Ciulli, A. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128653 · Cited by 58
S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells
Liu, T., Lo, H.-L., Wei, L.-S., Hsiao, H. H.-Y., & Yang, P. (2014) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000166 · Cited by 59
Molecular Pathways: Protein Methyltransferases in Cancer
Copeland, R. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0223 · Cited by 59
Self-citation
Determining direct binders of the Androgen Receptor using a high-throughput Cellular Thermal Shift Assay
Shaw, J., Leveridge, M., Norling, C., Karén, J., Molina, D. M., O’Neill, D. J., Dowling, J. E., Davey, P. R. J., Cowan, S., Dabrowski, M. A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-18650-x · Cited by 58
EZH2-mediated development of therapeutic resistance in cancer
Kaur, P., Shankar, E., & Gupta, S. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216706 · Cited by 64
Long Residence Time Inhibition of EZH2 in Activated Polycomb Repressive Complex 2
Aller, G. S. V., Pappalardi, M. B., Ott, H. M., Diaz, E., Brandt, M. A., Schwartz, B., Miller, W. H., Dhanak, D., McCabe, M. T., Verma, S. K., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb4008748 · Cited by 59
Histones and Their Modifications in Ovarian Cancer – Drivers of Disease and Therapeutic Targets
Marsh, D. J., Shah, J. S., & Cole, A. J. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00144 · Cited by 58
Connections between metabolism and epigenetics: mechanisms and novel anti-cancer strategy
Chen, C., Wang, Z., & Qin, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.935536 · Cited by 62
The histone methyltransferase DOT1L: regulatory functions and a cancer therapy target.
Wong, M., Polly, P., & Liu, T. (2015) · Europe PMC (PubMed Central) · Cited by 57
Naturally occurring anti-cancer agents targeting EZH2
Shahabipour, F., Caraglia, M., Majeed, M. A., Derosa, G., Maffioli, P., & Sahebkar, A. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.020 · Cited by 61
SWI/SNF catalytic subunits’ switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells
Wu, S., Fatkhutdinov, N., Fukumoto, T., Bitler, B. G., Park, P. H., Kossenkov, A. V., Trizzino, M., Tang, H., Zhang, L., Gardini, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06656-6 · Cited by 57
EZH 2: an emerging role in melanoma biology and strategies for targeted therapy
Tiffen, J. C., Gallagher, S. J., & Hersey, P. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12280 · Cited by 58
Polycomb group proteins and MYC: the cancer connection
Benetatos, L., Vartholomatos, G., & Hatzimichael, E. C. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1426-x · Cited by 57
Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro
Shen, J. K., Cote, G. M., Gao, Y., Choy, E., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2016) · Scientific Reports · doi:10.1038/srep25239 · Cited by 59
Methyltransferase Inhibitors: Competing with, or Exploiting the Bound Cofactor
de Freitas, R. F., Ivanochko, D., & Schapira, M. (2019) · Molecules · doi:10.3390/molecules24244492 · Cited by 57
The Roles of Retinoic Acid and Retinoic Acid Receptors in Inducing Epigenetic Changes
Urvalek, A. M., Laursen, K. B., & Gudas, L. J. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9050-5_7 · Cited by 58
WEE1 tyrosine kinase, a novel epigenetic modifier
Mahajan, K. N., & Mahajan, N. P. (2013) · Trends in Genetics · doi:10.1016/j.tig.2013.02.003 · Cited by 55
Chromatin modifications remodel cardiac gene expression
Mathiyalagan, P., Keating, S. T., Du, X., & El‐Osta, A. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu122 · Cited by 58
Epigenetic-based therapy: From single- to multi-target approaches
Benedetti, R., Conte, M., Iside, C., & Altucci, L. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.10.016 · Cited by 56
Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes
Scholze, H., Stephenson, R. E., Reynolds, R., Shah, S. B., Puri, R., Butler, S. D., Trujillo-Alonso, V., Teater, M. R., van Besien, H. J., Gibbs-Curtis, D., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002580 · Cited by 54
Targeting protein–protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?
Cierpicki, T., & Grembecka, J. (2015) · Immunological Reviews · doi:10.1111/imr.12244 · Cited by 53
Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs
Gelato, K. A., Adler, D., Ocker, M., & Haendler, B. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1134490 · Cited by 52
NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition
Drosos, Y., Myers, J., Xu, B., Mathias, K. M., Beane, E. C., Radko-Juettner, S., Mobley, R. J., Larsen, M. E., Piccioni, F., Ma, X., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.04.015 · Cited by 53
Synthetic Lethality in Cancer Therapeutics
Beijersbergen, R. L., Wessels, L. F. A., & Bernards, R. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-042016-073434 · Cited by 56
Targeting the MTF2–MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy
Maganti, H. B., Jrade, H., Cafariello, C., Rothberg, J. L. M., Porter, C. J., Yockell‐Lelièvre, J., Battaion, H. L., Khan, S. T., Howard, J. P., Li, Y., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0841 · Cited by 60
Prostate Cancer Epigenetics: From Basic Mechanisms to Clinical ImplicationsPreprint
Yegnasubramanian, S., Marzo, A. M. D., & Nelson, W. G. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030445 · Cited by 53

Authors: Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., Sacks, J. D., Raimondi, A., Majer, C. R., Song, J., Scott, M. P., Jin, L., Smith, J. J., Olhava, E. J., Chesworth, R., Moyer, M. P., Richon, V. M., Copeland, R. A., Keilhack, H., Pollock, R. M., & Kuntz, K. W.
Affiliations: Epizyme (United States) (US)
Corresponding author: Kuntz, Kevin W
ORCID: Knutson, Sarah K
Wigle, Tim J
Klaus, Christine R
Raimondi, Alejandra
Song, Jeffrey
Jin, Lei
Smith, Jesse J
Copeland, Robert A
Pollock, Roy M
Venue: Nature Chemical Biology
Publisher: Springer Science and Business Media LLC
Published: 2012-09-30
Volume: 8
Issue: 11
Pages: 890-896
ISSN: 1552-4450 (ISSN-L)
1552-4469
DOI: 10.1038/nchembio.1084
OpenAlex: W2017492512
Cited by: 776
References: 46
Citations by year: 2026: 20 · 2025: 29 · 2024: 29 · 2023: 39 · 2022: 38 · 2021: 49 · 2020: 42 · 2019: 44 · 2018: 60 · 2017: 83 · 2016: 78 · 2015: 97 · 2014: 89 · 2013: 69 · 2012: 10
FWCI: 34.74
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Chemical Biology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer-related gene regulation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: EZH2, H3K27me3, polycomb repressive complex 2, EZH2 inhibitors, non-Hodgkin lymphoma, oncogene addiction, apoptosis, histone methyltransferase inhibitors
MeSH terms: Enhancer of Zeste Homolog 2 Protein, Antineoplastic Agents, Cell Cycle, Dose-Response Relationship, Drug, Enzyme Inhibitors, Histones, Humans, Indazoles, Lymphoma, Lysine, Methylation, Pyridones, Structure-Activity Relationship, Molecular Structure, Cell Death, Point Mutation, Cell Proliferation, Polycomb Repressive Complex 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks